by Alison Bass | Dec 2, 2011 | antidepressants, antipsychotic drugs, clinical trials, conflicts of interest, drug marketing, FDA, ghostwriting, pharmaceutical industry
A new report from the U.S. Government Accountability office confirms something that Rose Firestein, the eponymous prosecutor in the title of Side Effects: A Prosecutor, a Whistleblower and Bestselling Antidepressant on Trial noticed way back in the ’90s: that...
by Alison Bass | Nov 2, 2011 | antipsychotic drugs, conflicts of interest, drug marketing, ghostwriting, patient care, pharmaceutical industry, scientific misconduct, Uncategorized
On November 28, the Texas Attorney General is expected to begin a landmark trial against Johnson & Johnson on charges that the pharmaceutical giant “subverted scientific integrity” by paying off academic psychiatrists and state officials to boost the...
by Alison Bass | Aug 3, 2011 | antipsychotic drugs, conflicts of interest, health care costs, university industry collaboration
Medicare and social services for vulnerable Americans are not the only programs on the chopping block with Washington’s deal to raise the debt ceiling and cut trillions of dollars in government spending. Looming ahead may be deep cuts in funding for medical and...
by Alison Bass | Jul 5, 2011 | antipsychotic drugs, conflicts of interest, pharmaceutical industry, university industry collaboration
Harvard Medical School finally wrapped up its three-year-old investigation of Dr. Joseph Biederman and two colleagues accused of failing to disclose extensive financial conflicts of interest, with essentially a slap on the wrist. In 2008, Congressional investigators...
